AgeX is a biotechnology company focused on developing therapeutics that target age-related degenerative diseases through cellular reprogramming and regenerative medicine techniques. Their approach aims to restore cellular function and improve healthspan, addressing the growing prevalence of age-related conditions.
Funding
$36M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related degenerative diseases are becoming increasingly prevalent, leading to a decline in cellular function and overall healthspan. Current treatments often manage symptoms rather than addressing the underlying causes of cellular aging.
Solution
AgeX is a biotechnology company developing therapeutics that target age-related degenerative diseases through cellular reprogramming and regenerative medicine techniques. Their approach focuses on restoring cellular function to improve healthspan. By employing cellular reprogramming, AgeX aims to rejuvenate cells and tissues affected by aging processes. This regenerative medicine approach seeks to address the root causes of age-related conditions, potentially leading to more effective and long-lasting treatments. The company's research and development efforts are directed towards creating therapies that can reverse or mitigate the effects of aging at the cellular level.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related degenerative diseases, as well as healthcare providers and researchers in the field of regenerative medicine.
Features
- Development of therapeutics based on cellular reprogramming techniques.
- Focus on regenerative medicine approaches to restore cellular function.
- Targeting the underlying causes of age-related degenerative diseases.
- Research and development of therapies to reverse or mitigate the effects of aging at the cellular level.